TabsDetailsBasic DetailsDate Posted: Tuesday, January 7, 2020Status: CompleteMedical Product: hydroxyureaHealth Outcome(s): sickle cell anemiause by indicationDescription: The purpose of this request was to characterize hydroxyurea use among members with sickle cell anemia (SCA). Data from January 1, 2000 to September 30, 2015 from 17 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in these reports. This request was distributed on February 28, 2018. This request contains two reports.Report 1 estimated the number patients with SCA, the number of SCA patients who were dispensed hydroxyurea, and the average number of hospitalizations and emergency department visits per person-year among those patients in the SDD. Report 2 examines utilization patterns of hydroxyurea among patients with SCA in the SDD. Read More Deliverables (2)Sentinel Modular Program Report: Hydroxyurea Use in Patients with Sickle Cell Anemia, Report 1Sentinel Modular Program Report: Hydroxyurea Use in Patients with Sickle Cell Anemia, Report 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - September 30, 2015Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)
